Australia markets closed
  • ALL ORDS

    7,577.20
    +18.40 (+0.24%)
     
  • ASX 200

    7,312.30
    +9.80 (+0.13%)
     
  • AUD/USD

    0.7710
    -0.0045 (-0.58%)
     
  • OIL

    70.78
    +0.49 (+0.70%)
     
  • GOLD

    1,879.50
    -16.90 (-0.89%)
     
  • BTC-AUD

    46,375.66
    -2,420.97 (-4.96%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • AUD/EUR

    0.6363
    -0.0002 (-0.03%)
     
  • AUD/NZD

    1.0809
    +0.0040 (+0.37%)
     
  • NZX 50

    12,550.39
    +32.38 (+0.26%)
     
  • NASDAQ

    13,998.30
    +37.95 (+0.27%)
     
  • FTSE

    7,134.06
    +45.88 (+0.65%)
     
  • Dow Jones

    34,479.60
    +13.36 (+0.04%)
     
  • DAX

    15,693.27
    +122.05 (+0.78%)
     
  • Hang Seng

    28,842.13
    +103.25 (+0.36%)
     
  • NIKKEI 225

    28,948.73
    -9.83 (-0.03%)
     

Nigel Wray-backed Belluscura to raise £15 million for oxygen concentrator rollout

·1-min read
<p>The funds will be used for the roll out of its lightweight and portable oxygen concentrators </p> (Belluscura)

The funds will be used for the roll out of its lightweight and portable oxygen concentrators

(Belluscura)

A medical devices business backed by former Saracens rugby club chairman Nigel Wray is set to raise £15 million after revealing plans for a stock market listing.

Belluscura will use the funds for the roll out of its lightweight and portable oxygen concentrators that can replace cumbersome metal cylinders in treating lung diseases.

Its X-PLO2R device, which received approval from US regulators in March, is able to deliver up to 95% pure oxygen to patients 24 hours a day to help improve quality of life.

The London and Texas-based company will also look to progress other patents relating to oxygen enrichment devices and treatments.

Belluscura is expected to be valued at between £50 million and £55 million on AIM following the placing of shares with institutions later this month. Wray holds a 17% stake.

SPARK Advisory Partners is acting as adviser, while Dowgate Capital is sole broker and bookrunner on the placing.

Read More

Love Hemp and Togetherall partner to give CBD fans free mental support

Boom time at Numis means big banker bonuses

Holiday Inn owner IHG sees US and China-fuelled bounce-back in demand